Flexible Contraceptive Ring Lasts for Whole Year
By HospiMedica International staff writers Posted on 30 Aug 2018 |
Image: The Annovera reusable contraceptive ring (Photo courtesy of Hallie Easley / Population Council).
A new self-administered hormonal contraceptive formed as a reusable, flexible silicone ring can prevent unwanted pregnancies for up to an entire year.
The Annovera contraceptive ring, developed by the global nonprofit organization Population Council (New York, NY, USA), is a soft, reusable flexible silicone ring (57 mm in diameter) loaded with segesterone acetate and ethinyl estradiol that can be inserted and removed by a woman herself. It is placed vaginally for 21 days and removed for the next seven. When not in use, it is washed and stored in a compact case, withstanding temperatures of up to 30°C, an important consideration for distribution and use in low-resource settings.
Results of the Phase 3 trial, which enrolled a total of 2,308 women across 27 study sites in the United States, Latin America, Europe, and Australia, showed that Annovera was 97.3% effective in preventing pregnancy when used as directed, with a similar risk profile to other combined hormonal contraceptives. Similarly, a boxed warning related to increased cardiovascular risk warns users who smoke. As yet, Annovera has not been adequately evaluated in women with a body mass index (BMI) greater than 29 kg/m2.
“Nearly half of all pregnancies in the United States are unintended, which can increase health risks for mom and baby,” said Julia Bunting, president of the Population Council. “For more than 60 years, the Population Council has been at the vanguard of global efforts to develop innovative family planning methods that meet women’s needs. Having a single contraceptive system that provides a full year of protection while under a woman’s control could be a game-changer for some women.”
Annovera is the sixth contraceptive technology that Population Council researchers have developed to address family planning needs around the world and brought to market through commercialization agreements, which are in use by an estimated 170 million women worldwide. Other contraceptives developed by the Population Council include the copper intrauterine device (IUD) ParaGard; the Mirena intrauterine system; the contraceptive implants Norplant and Jadelle; and Progering, a contraceptive vaginal ring for breastfeeding women.
Related Links:
Population Council
The Annovera contraceptive ring, developed by the global nonprofit organization Population Council (New York, NY, USA), is a soft, reusable flexible silicone ring (57 mm in diameter) loaded with segesterone acetate and ethinyl estradiol that can be inserted and removed by a woman herself. It is placed vaginally for 21 days and removed for the next seven. When not in use, it is washed and stored in a compact case, withstanding temperatures of up to 30°C, an important consideration for distribution and use in low-resource settings.
Results of the Phase 3 trial, which enrolled a total of 2,308 women across 27 study sites in the United States, Latin America, Europe, and Australia, showed that Annovera was 97.3% effective in preventing pregnancy when used as directed, with a similar risk profile to other combined hormonal contraceptives. Similarly, a boxed warning related to increased cardiovascular risk warns users who smoke. As yet, Annovera has not been adequately evaluated in women with a body mass index (BMI) greater than 29 kg/m2.
“Nearly half of all pregnancies in the United States are unintended, which can increase health risks for mom and baby,” said Julia Bunting, president of the Population Council. “For more than 60 years, the Population Council has been at the vanguard of global efforts to develop innovative family planning methods that meet women’s needs. Having a single contraceptive system that provides a full year of protection while under a woman’s control could be a game-changer for some women.”
Annovera is the sixth contraceptive technology that Population Council researchers have developed to address family planning needs around the world and brought to market through commercialization agreements, which are in use by an estimated 170 million women worldwide. Other contraceptives developed by the Population Council include the copper intrauterine device (IUD) ParaGard; the Mirena intrauterine system; the contraceptive implants Norplant and Jadelle; and Progering, a contraceptive vaginal ring for breastfeeding women.
Related Links:
Population Council
Latest Patient Care News
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
- Innovative and Highly Customizable Medical Carts Offer Unlimited Configuration Possibilities
- Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients
- Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases
- Wearable Cardioverter Defibrillator System Protects Patients at Risk of Sudden Cardiac Arrest
- World's First AI-Ready Infrasound Stethoscope Listens to Bodily Sounds Not Audible to Human Ear